MedTrace Logo

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

NCT01188811 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-02-02

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.

Conditions

  • Multiple Sclerosis, Chronic Progressive

Interventions

DRUG

lipoic acid

1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.

DRUG

Placebo

The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Rebecca Spain, MD MSPH · VA Portland Health Care System, Portland, OR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01188811 on ClinicalTrials.gov